The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
The aim of this study was to review and compare types of reimbursement recommendations for orphan drugs issued by eight European health technology assessment (HTA) agencies and the reimbursement status of these drugs in the corresponding countries. Separate calculations were also performed for three sub-groups: ultra-orphan drugs, oncology orphan drugs and other (non-ultra, non-oncology) orphan drugs.



We reviewed drugs authorized by the European Medicine Agency (EMA) between 1 November 2002 and 30 September 2015. Among these, we identified 101 orphan drugs. Seventy-nine of them were assessed by eight European HTA agencies. The average rates of positive, conditional and negative reimbursement recommendations issued by these agencies were 55.7 %, 15.3 % and 29.0 %, respectively. On average, 21.2 % of EMA-authorized orphan drugs were reimbursed in the eight European countries studied: 49.0 % of those with positive, 53.6 % of those with conditional, and 16.0 % of those with negative reimbursement recommendations. In addition, 5.4 % of orphan drugs that had not been assessed by any of the eight HTA agencies were also reimbursed. The shares of oncology, ultra, and other orphan drugs that were assessed by HTA agencies were similar, with the lowest share observed in ultra-orphan drugs (72 %) and the highest in other orphan drugs (80 %). In terms of reimbursement, 20 % of oncology orphan drugs, 25 % of ultra-orphan drugs and 21 % of other orphan drugs were reimbursed.



Reimbursement of orphan drugs does not always correspond to the type of HTA recommendation. While the highest rate of reimbursement is observed (unsurprisingly) among drugs with positive or conditional recommendation, a high rate of reimbursement (11 %) is also observed among ultra-orphan drugs that had never been assessed by any HTA agency.
Drug Management Department, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, ul. Grzegórzecka 20, 31-531, Kraków, Poland. pawel.kawalec@uj.edu.pl.
Paweł
P
Kawalec
European Observatory on Health Systems and Policies, London, United Kingdom.|London School of Economics, Health and Social Care, London, United Kingdom.
Anna
A
Sagan
Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland.
Andrzej
A
Pilc
D003657:Decision Making; D005060:Europe; D006291:Health Policy; D006801:Humans; D009965:Orphan Drug Production / Q000191:economics* / Q000331:legislation & jurisprudence / Q000592:standards; D012051:Reimbursement Mechanisms / Q000592:standards / Q000706:statistics & numerical data; D013673:Technology Assessment, Biomedical / Q000331:legislation & jurisprudence / Q000592:standards*
Drug reimbursement; Health technology assessment; Oncology orphan drugs; Orphan drugs; Reimbursement decision; Reimbursement status; Ultra-orphan drugs